CN117625606A - miR-CM4 of Phellinus linteus and application thereof - Google Patents
miR-CM4 of Phellinus linteus and application thereof Download PDFInfo
- Publication number
- CN117625606A CN117625606A CN202311499739.7A CN202311499739A CN117625606A CN 117625606 A CN117625606 A CN 117625606A CN 202311499739 A CN202311499739 A CN 202311499739A CN 117625606 A CN117625606 A CN 117625606A
- Authority
- CN
- China
- Prior art keywords
- mir
- skin
- seq
- mirna
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000001727 Tropicoporus linteus Species 0.000 title claims abstract description 26
- 239000002773 nucleotide Substances 0.000 claims abstract description 24
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000002679 microRNA Substances 0.000 claims description 38
- 239000000839 emulsion Substances 0.000 claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 18
- 239000003995 emulsifying agent Substances 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 17
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 108091070501 miRNA Proteins 0.000 claims description 11
- -1 polydimethylsiloxane Polymers 0.000 claims description 10
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 9
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 9
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 9
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 9
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 9
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 9
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 9
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 9
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 6
- 108091081021 Sense strand Proteins 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 61
- 239000002158 endotoxin Substances 0.000 abstract description 23
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 22
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 15
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 230000014509 gene expression Effects 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 5
- 210000004927 skin cell Anatomy 0.000 abstract description 5
- 230000028709 inflammatory response Effects 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract 1
- 108700011259 MicroRNAs Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 21
- 239000000047 product Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000006749 inflammatory damage Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000008681 Phellinus linteus extract Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 101710188535 RNA ligase 2 Proteins 0.000 description 1
- 101710204104 RNA-editing ligase 2, mitochondrial Proteins 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 238000012167 Small RNA sequencing Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of biotechnology and medicine, relates to the separation and identification of miR-CM4 from Phellinus linteus, and particularly relates to application of miR-CM 4. The miR-CM4 has a nucleotide sequence shown as SEQ ID NO.3 and has good anti-inflammatory activity. The miR-CM4 can resist inflammatory response induced by Lipopolysaccharide (LPS) and ultraviolet radiation when applied to skin cells or tissues, and can reduce the expression of inflammatory factors. The invention also provides a skin external preparation containing miR-CM4, and the skin external preparation has an anti-inflammatory effect. Provides a new research direction and development foundation for the development of anti-inflammatory skin care products.
Description
The application is a divisional application of an invention patent application 202111573093.3, the application date of 202111573093.3 is 2021, 12 and 21, the application number is 202111573093.3, and the invention name is: miRNA of Phellinus linteus and application thereof are provided.
Technical field:
the invention belongs to the field of biotechnology and medicine, and relates to the separation and identification of miRNA from phellinus linteus, in particular to miR-CM4 and application thereof.
The background technology is as follows:
skin is the first line of defense of the human body and is most susceptible to damage, inflammation or aging of the skin due to the external environment. When external stimuli occur, such as contact with stimulus sources such as air pollutants, ultraviolet rays, physical injury and the like, the immune system of the skin can start signals, release various inflammatory factors, cause acceleration of blood flow and increase of permeability of blood vessels, and cause inflammatory reactions of the skin, and symptoms can comprise redness, heat, itching, sensitivity, swelling and the like. One of the most pronounced acute effects of ultraviolet light on the skin is the induction of inflammation. UVB induces a cascade of cytokines, vasoactive and neuroactive mediators in the skin that together lead to an inflammatory response and to "sunburn". Many people suffer from skin inflammation due to frequent exposure to different irritants and allergens, which can lead to serious health problems if not treated in time. In modern society, with the continuous understanding of the importance of skin care, the skin care knowledge is increased, skin care has become a daily use, and anti-inflammatory repair products have gradually become one of cosmetics used daily by people. Therefore, the research and development of raw materials and mechanisms of anti-inflammatory skin care products have great practical significance.
Lipopolysaccharide (LPS), which is a component of the outer wall of the cell wall of gram-negative bacteria, is a common endotoxin, and consists mainly of lipid and polysaccharide. It can activate mononuclear macrophages, endothelial cells, epithelial cells and the like through a cell signal transduction system, synthesize and release various cytokines and inflammatory mediators, and further cause a series of inflammatory reactions, leading to the appearance of inflammation. Induction of cellular inflammation using LPS is one of the methods of modeling cellular inflammation. In addition, after ultraviolet irradiation, the number of epidermal cell layers and the thickness of epidermis are increased, more dead skin is formed, and the blockage degree of hair follicles is increased, so that the inflammation of vaccinia is worsened. UV irradiation can simulate sun irritation and build up an inflammatory or aging model.
Phellinus linteus is a typical pharmaceutical fungus and contains compounds such as polysaccharides, polyphenols, and flavonoids. More and more researches show that the phellinus linteus plays a remarkable regulating and controlling role in resisting tumor, protecting liver, reducing inflammatory reaction, controlling blood sugar and the like. For example, the polysaccharide isolated from it can inhibit the expression of various inflammatory factors in cells. In addition, the water-soluble extract thereof plays an immunoregulatory role in atopic dermatitis. Phellinus linteus extract was listed in the catalog of used cosmetic raw materials (2021 edition). Currently, phellinus linteus extracts have been used in various skin care and cosmetic formulations.
microRNA (miRNA) is a class of endogenous non-coding RNA of about 19-25nt in length. miRNA is involved in gene posttranscriptional regulation, can regulate the growth and development of cells and organisms, and is related to human diseases. More and more researches show that exogenous plant miRNAs can regulate the expression of target genes of mammals, so that the cross-border regulation is realized. For example, zhang Chenyu found that miR2911 in honeysuckle can be absorbed by mice, inhibiting viral replication by targeting alphavirus. The miRNA in the phellinus linteus can carry out cross-boundary regulation on human skin cells, and plays an anti-inflammatory role. The method has great potential application value in the research and development of anti-inflammatory skin care products.
The invention comprises the following steps:
the invention aims to provide miRNAs of phellinus linteus, namely miR-CM2, miR-CM3, miR-CM4 and miR-CM5 and application thereof, wherein the miR-CM2, miR-CM3, miR-CM4 and miR-CM5 can reduce the expression of inflammatory factors in an inflammation model, and have potential values in the development and application of anti-inflammatory skin care products.
One of the technical schemes provided by the invention is miRNA from Phellinus linteus, which is miR-CM2, miR-CM3, miR-CM4 or miR-CM5 respectively;
the miR-CM2 has a nucleotide sequence shown in SEQ ID NO. 1;
the miR-CM3 has a nucleotide sequence shown as SEQ ID NO. 2;
the miR-CM4 has a nucleotide sequence shown in SEQ ID NO. 3;
the miR-CM5 has a nucleotide sequence shown as SEQ ID NO. 4;
further, the precursor sequence MIR-CM2 of the miR-CM2 has a nucleotide sequence shown in SEQ ID NO. 5;
further, the precursor sequence MIR-CM3 of the miR-CM3 has a nucleotide sequence shown in SEQ ID NO. 6;
further, the precursor sequence MIR-CM4 of the miR-CM4 has a nucleotide sequence shown in SEQ ID NO. 7;
further, the precursor sequence MIR-CM5 of the miR-CM5 has a nucleotide sequence shown in SEQ ID NO. 8;
further, the DNA encoding the precursor sequence MIR-CM2 has a nucleotide sequence shown as SEQ ID NO. 9;
further, the DNA encoding the precursor sequence MIR-CM3 has a nucleotide sequence shown in SEQ ID NO. 10;
further, the DNA encoding the precursor sequence MIR-CM4 has a nucleotide sequence shown as SEQ ID NO. 11;
further, the DNA encoding the precursor sequence MIR-CM5 has the nucleotide sequence shown in SEQ ID NO. 12.
The second technical scheme provided by the invention is application of miR-CM2, miR-CM3, miR-CM4 or miR-CM5;
further, the use is the use of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 in skin care products, cosmetics or cosmetic products, and in the preparation of products for preventing or treating photoaging, in particular in the preparation of anti-inflammatory products.
The third technical scheme provided by the invention is a skin external preparation containing the miR-CM2, miR-CM3, miR-CM4 or miR-CM5;
further, the skin external agent includes, but is not limited to, a skin care product, a cosmetic, an application agent, or the like;
the coating agent comprises, but is not limited to, oil agent, water agent, ointment or gel agent and the like;
further, the addition amount of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 in the skin external agent is 0.2-5% (weight percentage);
further, the external preparation for skin is in the form of at least one of water, essence, gel, emulsion, skin base solution or cream;
further, an emulsion containing miR-CM2 comprises the following components (in percentage by weight): 0.01-0.05% of EDTA disodium, 2-5% of glycerol, 0.05-0.2% of xanthan gum, 0.1-0.3% of p-hydroxyacetophenone, 0.5-3% of Montanov L-emulsifier, 0.5-3% of ARLACEL170 emulsifier, 0.1-0.5% of glycerol stearate, 0.5-3% of cetostearyl alcohol, 2-6% of caprylic/capric triglyceride, 0.5-3% of polydimethylsiloxane, 0.1-0.5% of methyl propylene glycol, 0.5-3% of polyethyleneimine-1500, 0.5-3% of sodium hyaluronate, 0.2-5% of miR-CM and the balance deionized water;
furthermore, miR-CM2 added into the emulsion can be a single-stranded nucleic acid molecule or a double-stranded nucleic acid molecule; the single-stranded nucleic acid molecule is a nucleic acid molecule synthesized according to the nucleotide sequence in SEQ ID NO. 1; the double-stranded nucleic acid molecule is synthesized according to the nucleotide sequence in SEQ ID NO.1 and the complementary sequence thereof;
further, an emulsion containing miR-CM3 comprises the following components (in percentage by weight): 0.01-0.05% of EDTA disodium, 2-5% of glycerol, 0.05-0.2% of xanthan gum, 0.1-0.3% of p-hydroxyacetophenone, 0.5-3% of Montanov L-emulsifier, 0.5-3% of ARLACEL170 emulsifier, 0.1-0.5% of glycerol stearate, 0.5-3% of cetostearyl alcohol, 2-6% of caprylic/capric triglyceride, 0.5-3% of polydimethylsiloxane, 0.1-0.5% of methyl propylene glycol, 0.5-3% of polyethyleneimine-1500, 0.5-3% of sodium hyaluronate, 0.2-5% of miR-CM and the balance deionized water;
furthermore, miR-CM3 added into the emulsion can be a single-stranded nucleic acid molecule or a double-stranded nucleic acid molecule; the single-stranded nucleic acid molecule is a nucleic acid molecule synthesized according to the nucleotide sequence in SEQ ID NO. 2; the double-stranded nucleic acid molecule is synthesized according to the nucleotide sequence in SEQ ID NO.2 and the complementary sequence thereof;
further, an emulsion containing miR-CM4 comprises the following components (in percentage by weight): 0.01-0.05% of EDTA disodium, 2-5% of glycerol, 0.05-0.2% of xanthan gum, 0.1-0.3% of p-hydroxyacetophenone, 0.5-3% of Montanov L-emulsifier, 0.5-3% of ARLACEL170 emulsifier, 0.1-0.5% of glycerol stearate, 0.5-3% of cetostearyl alcohol, 2-6% of caprylic/capric triglyceride, 0.5-3% of polydimethylsiloxane, 0.1-0.5% of methyl propylene glycol, 0.5-3% of polyethyleneimine-1500, 0.5-3% of sodium hyaluronate, 0.2-5% of miR-CM and the balance deionized water;
furthermore, miR-CM4 added into the emulsion can be a single-stranded nucleic acid molecule or a double-stranded nucleic acid molecule; the single-stranded nucleic acid molecule is a nucleic acid molecule synthesized according to the nucleotide sequence in SEQ ID NO. 3; the double-stranded nucleic acid molecule is synthesized according to the nucleotide sequence in SEQ ID NO.3 and the complementary sequence thereof;
further, an emulsion containing miR-CM5 comprises the following components (in percentage by weight): 0.01-0.05% of EDTA disodium, 2-5% of glycerol, 0.05-0.2% of xanthan gum, 0.1-0.3% of p-hydroxyacetophenone, 0.5-3% of Montanov L-emulsifier, 0.5-3% of ARLACEL170 emulsifier, 0.1-0.5% of glycerol stearate, 0.5-3% of cetostearyl alcohol, 2-6% of caprylic/capric triglyceride, 0.5-3% of polydimethylsiloxane, 0.1-0.5% of methyl propylene glycol, 0.5-3% of polyethyleneimine-1500, 0.5-3% of sodium hyaluronate, 0.2-5% of miR-CM and the balance deionized water;
furthermore, miR-CM5 added into the emulsion can be a single-stranded nucleic acid molecule or a double-stranded nucleic acid molecule; the single-stranded nucleic acid molecule is a nucleic acid molecule synthesized according to the nucleotide sequence in SEQ ID NO. 4; the double-stranded nucleic acid molecule is synthesized according to the nucleotide sequence in SEQ ID NO.4 and the complementary sequence thereof;
preferably, the addition amount of miR-CM2 (or miR-CM3 or miR-CM4 or miR-CM 5) is 0.5-1%;
preferably, the emulsion containing miR-CM2 (or miR-CM3 or miR-CM4 or miR-CM 5) comprises the following components (in weight percent): EDTA disodium 0.03%, glycerol 4%, xanthan gum 0.1%, p-hydroxyacetophenone 0.2%, montanov L-emulsifier 1%, ARLACEL170 emulsifier 1%, glyceryl stearate 0.3%, cetostearyl alcohol 1%, caprylic/capric triglyceride 4%, polydimethylsiloxane 1%, methyl propylene glycol 0.35%, polyethylene imine-1500 1%, sodium hyaluronate 1%, miR-CM2 (or miR-CM3 or miR-CM4 or miR-CM 5) 0.75%, and the balance deionized water.
The fourth technical scheme provided by the invention is the application of the skin external preparation containing miR-CM2, miR-CM3, miR-CM4 or miR-CM5, in particular the application of the emulsion containing miR-CM2, miR-CM3, miR-CM4 or miR-CM5, and the emulsion can resist ultraviolet-induced inflammation and reduce the increase of the thickness of epidermis caused by ultraviolet irradiation.
The invention has the beneficial effects that:
the invention screens out a novel phellinus linteus miRNA (miR-CM 2, miR-CM3, miR-CM4 and miR-CM 5) and precursors thereof, namely MIR-CM2, MIR-CM3, MIR-CM4 and MIR-CM5. The miR-CM2/CM3/CM4/CM5 has good anti-inflammatory activity, and the miR-CM2/CM3/CM4/CM5 is applied to skin cells or tissues, so that the anti-inflammatory effect induced by Lipopolysaccharide (LPS) and ultraviolet irradiation can be resisted, and the expression of inflammatory factors is reduced.
The invention provides a formula of a basic skin care product containing miR-CM2, miR-CM3, miR-CM4 or miR-CM5, and the basic skin care product has an anti-inflammatory effect. Provides a new research direction and development foundation for the development of anti-inflammatory skin care products.
The miR-CM2, miR-CM3, miR-CM4 or miR-CM5 disclosed by the invention can provide a mechanism support for research of anti-inflammatory skin care products of phellinus linteus extracts, and a wider space is provided for research and development of the anti-inflammatory skin care products.
Description of the drawings:
FIG. 1 is a secondary structure of precursor MiR-CM2, miR-CM3, miR-CM4 and MiR-CM5 of miR-CM2, miR-CM3, miR-CM4 and miR-CM5.
FIG. 2 is a graph showing the protective effects of miR-CM2, miR-CM3, miR-CM4 and miR-CM5 on skin cells under LPS stimulation.
FIG. 3 is a graph showing the expression of inflammatory factors (IL-1β, IL-6, TNF- α, NF- κB) when miR-CM2, miR-CM3, miR-CM4 or miR-CM5 is applied to skin cells.
In each bar graph of fig. 2 and 3, the following steps are sequentially performed from left to right: ctrl group, LPS group, lps+mir-CM2, lps+mir-CM3 group, lps+mir-CM4 group, lps+mir-CM5 group.
FIG. 4 variation in skin epidermis thickness before and after application of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 skin care products in mouse skin;
wherein, the left side is HE staining of the skin of the mouse; the right is the corresponding skin thickness statistical graph.
Detailed Description
The technical solutions of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The experimental procedures in the following examples, unless otherwise specified, are conventional in the art. The materials, reagents and the like used, unless otherwise specified, are all commercially available.
In the present invention, miR represents miRNA;
in the present invention, miR-CM2/CM3/CM4/CM5 represents "miR-CM2, miR-CM3, miR-CM4 or miR-CM5";
phellinus linteus (Phellinus linteus) used in the present invention is purchased from North Nanopsis (BNCC), strain number BNCC109781.
Example 1 screening and identification of miRNAs
1. Preparation of samples
The extraction of the RNA sample may be from a lysate of Phellinus linteus or from an exosome of Phellinus linteus. For lysates: cutting Phellinus linteus in PBS under high pressure, and centrifuging at high speed to obtain supernatant, which is lysate of Phellinus linteus. For exosomes: the exosome of Phellinus linteus is obtained by homogenizing Phellinus linteus, and centrifuging at differential speed. The dead cells were removed by first centrifugation at 3000 Xg for 30 minutes, the supernatant was collected and centrifuged at 10000 Xg for 60 minutes to remove cell debris. The resulting supernatant was further centrifuged at 150000Xg for 90 minutes, and the exosomes (pellet) were suspended in PBS buffer.
RNA extraction and quality detection
Total RNA from the exosome samples was extracted using Trizol (Siemens, america) method. Detecting the integrity of RNA by agarose gel electrophoresis, wherein the electrophoresis shows that 28S and 18S bands are clear and have no degradation; detecting the concentration and purity of RNA by using an ultra-micro spectrophotometer (Tiangen, background), wherein the OD260/280 value is between 1.8 and 2.2, and the OD260/230 is more than or equal to 2.0, which indicates that the purity of the RNA is qualified. The concentration of the RNA sample is more than or equal to 200 ng/. Mu.L, and the total amount is more than or equal to 2. Mu.g. The RNA preliminary detection quality is qualified, so that the construction of a downstream high-quality small RNA-seq library is ensured. Further quality control and miRNA sequencing were performed.
3. Library construction:
the qualified RNA is used for constructing a miRNA library, a proper amount of total RNA is taken for joint connection reaction, a phosphate group is arranged at the 5 'end of the mature miRNA, the 3' end is hydroxyl, the structure is different from other RNA, and under the action of T4 RNA ligase 2 and T4 RNA ligase, 3 'joints and 5' joints with known sequences are added at the two ends. For RNA with 5 'and 3' linkers attached, cDNA of the first strand is synthesized using reverse transcription complementary to the sequence on the linker. And (3) taking the reaction product of the step as a template, and synthesizing and amplifying a double-chain library of miRNA by using PCR. Isolation of miRNA library with insert size of 22-24nt by polyacrylamide gel electrophoresis. And (5) performing quality inspection and quantitative evaluation on the constructed sequencing library to determine whether the sequencing library is suitable for being put on machine.
4. Sequencing on machine
And diluting the sample which is qualified in quality inspection, and loading the sample according to the corresponding proportion according to the sequencing flux requirements of different samples. The library was sequenced using an Illumina high throughput sequencing platform, a double ended sequencing strategy.
5. Bioinformatic analysis (including novel miRNA prediction and expression analysis)
In order to ensure the quality of information analysis, the original sequencing sequences (raw reads) obtained by sequencing are filtered to obtain clean reads for subsequent analysis. Quality filtration was performed using FASTX-Toolkit software. And carrying out small RNA length distribution statistics on the sequences after quality control, wherein miRNAs are concentrated at 21nt or 22nt. In addition, BLAST comparison is carried out on the sequences after quality control and mature miRNA sequences of corresponding species in the miRBase database, and the sequences are compared with the Rfam database and the reference genome, so that the sequencing result is subjected to preliminary evaluation. The results were annotated for different types of Small RNAs.
Novel miRNA prediction and expression analysis. Because the hairpin structure of the miRNA precursor can be used for predicting miRNA, the miRNA can be compared to a genome sequence, the sequences at two sides of the miRNA can be intercepted for predicting the secondary structure of the RNA, and the novel miRNA can be obtained by combining with the information such as the Dicer enzyme binding site, the free energy of the secondary structure and the like. Comparing reads with a reference genome by adopting mirdrep 2 software, and according to the comparison result of the reads and the genome, combining homologous miRNA sequences of related species, such as RNA secondary structures of RNAfold and the like, predicting and identifying new miRNA mature bodies (Star miRNA and material miRNA) and precursor sequences of the species, and counting the expression condition of the new miRNA of each sample.
Through the separation and identification, four novel miRNAs from Phellinus linteus are respectively named as miR-CM2, miR-CM3, miR-CM4 and miR-CM5. The secondary structure is shown in figure 1, and the figures show that stable stem-loop structures similar to miRNA precursors are formed, the mature sequences of the stable stem-loop structures are shown in sequence tables SEQ ID NO. 1-NO. 4, the precursor sequences of the stable stem-loop structures are shown in sequence tables SEQ ID NO. 5-NO. 8, and the encoding genes of the precursor sequences of the stable stem-loop structures are shown in sequence tables SEQ ID NO. 9-NO. 12.
SEQ ID NO.1 (miR-CM 2 mature sequence): uccucaagguuauccgua (18 bp).
SEQ ID NO.2 (miR-CM 3 mature sequence): ccggugcgcucucgacagcc (20 bp).
SEQ ID NO.3 (miR-CM 4 mature sequence): acguguggauccagacggguu (21 bp). SEQ ID NO.4 (miR-CM 5 mature sequence): uauuccauuccguccauccu (20 bp).
Example 2miR-CM 2-CM 5 reduced inflammatory injury of HaCaT cells caused by LPS
CCK8 experiment
1) Preparation of cell samples
Human immortalized epidermal cells (HaCaT cells) were cultured in DMEM (Gibco, U.S.) supplemented with 10% fetal bovine serum (BI, israel) and 100U/mL penicillin streptomycin cocktail (Menlam, china) and at 37℃and 5% CO concentration 2 Growing in an incubator;
and respectively transfecting miR-CM2 miics, miR-CM3 miics, miR-CM4 miics and miR-CM5 miics into the cultured HaCaT cells through Lipo2000 transfection reagent (Siemeaway, U.S.) and pre-protecting for 24 hours. LPS was added to each well (96-well plate) at a final concentration of 1. Mu.g/mL, and CCK8 assay (experimental group) was performed after 6h of stimulation.
Control group (Ctrl group): the normal culture of the human immortalized epidermal cells (HaCaT cells) does not carry out any treatment (without pre-protection and LPS stimulation); the model group (LPS group) was not pre-protected, only LPS stimulated; the experimental group (LPS+miR-CM 2/CM3/CM4/CM5 group) was pre-protected and LPS stimulated.
Transfection protocol: taking a 24-well plate as an example, other culture materials were adjusted for transfection scale with reference to the instructions, all numbers and volumes were calculated per well. Cells were inoculated in 500 μl of antibiotic-free medium and allowed to fuse up to 50% of the time during transfection. The amount of cells per well at the time of transfection was as follows: 20pmol of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 are diluted with 50. Mu.L of Opti-MEM culture medium, respectively, and gently mixed. mu.L of Lipo2000 was diluted in 50. Mu.L of Opti-MEM medium and incubated for 5min at room temperature. The first two solutions were mixed (to make the total volume 100. Mu.L), gently mixed, and left at room temperature for 20 minutes to form 100. Mu.L of transfection solution. mu.L of the transfection solution was added to each well of cells, and the mixture was gently shaken. (the present invention relates to the transfection procedure using this method unless otherwise specified).
miR-CM2, miR-CM3, miR-CM4, miR-CM5, namely miR-CM2 analogue, miR-CM3 analogue, miR-CM4 analogue and miR-CM5 analogue, which are double-stranded sequences, wherein:
miR-CM2 mimics：
the sense strand sequence is: 5'-uccucaagguuauccgua-3' (with miR-CM2, SEQ ID NO. 1);
the antisense strand sequence is: 5'-cggauaaccuugaggauu-3' (SEQ ID NO. 13).
miR-CM3 mimics：
The sense strand sequence is: 5'-ccggugcgcucucgacagcc-3' (with miR-CM3, SEQ ID NO. 2);
the antisense strand sequence is: 5'-cugucgagagcgcaccgguu-3' (SEQ ID NO. 14).
miR-CM4 mimics：
The sense strand sequence is: 5'-acguguggauccagacggguu-3' (with miR-CM4, SEQ ID NO. 3); the antisense strand sequence is: 5'-cccgucuggauccacacguuu-3' (SEQ ID NO. 15).
miR-CM5 mimics：
The sense strand sequence is: 5'-uauuccauuccguccauccu-3' (with miR-CM5, SEQ ID NO. 4);
the antisense strand sequence is: 5'-gauggacggaauggaauauu-3' (SEQ ID NO. 16).
2) Cell viability assay
Cell viability was measured using Cell Counting Kit-8 (CCK-8) (APExBIO, USA).
Mu.l of CCK-8 solution was added to each well of the 96-well plate. The plates were placed in an incubator for 1 hour. Absorbance at 450nm was measured using an enzyme-labeled instrument. The more the cells proliferate, the darker the color; the more cytotoxic the more light the colour.
As can be seen from fig. 2, 1 μg/ml of LPS stimulation significantly reduced the cell viability of HaCaT cells, reducing the survival rate of HaCaT cells. And the pre-protection of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 obviously improves the reduction of the activity of HaCaT cells caused by LPS of 1 mu g/ml. The result shows that the pre-protection of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 can reduce the damage degree of cells and reduce the decrease of the cell viability in the inflammatory damage of the cells caused by LPS treatment.
2. Real-time fluorescent quantitative PCR detection of gene expression
1) Preparation of cell samples
Preparation of cell samples was performed as in example 2, step 1.
2) Extraction of Total RNA
Total RNA was extracted from the samples by Trizol (Siemens, USA) method. The integrity and purity of the RNA samples were checked as in example 1, step 2.
3) Reverse transcription
cDNA was synthesized by reverse transcription using Hifair III 1st Strand cDNA Synthesis SuperMix for qPCR (gDNA digester plus) (next holy, shanghai) kit. The removal of genomic residual genomic DNA and reverse transcription system was as follows:
the following mixture was prepared in an RNase-free centrifuge tube, and gently swirled and mixed. Incubate at 42℃for 2min.
Preparation of reverse transcription reaction System (20. Mu.L System)
25 ℃ for 5min;55 ℃ for 15min;85 ℃ for 5min. The obtained cDNA was stored at-20 ℃.
4) qPCR experiment
qPCR was performed using Hieff UNICON Universal Blue qPCR SYBR Green Master Mix (next holy, shanghai).
The primers used for detection were as follows:
IL-1. Beta. Upstream primer: CCACAGACCTTCCAGGAGAATG (SEQ ID NO. 17); IL-1 beta downstream primer: GTGCAGTTCAGTGATCGTACAGG (SEQ ID NO. 18).
IL-6 upstream primer: AGACAGCCACTCACCTCTTCAG (SEQ ID NO. 19);
IL-6 downstream primer: TTCTGCCAGTGCCTCTTTGCTG (SEQ ID NO. 20).
TNF- α upstream primer: CTCTTCTGCCTGCTGCACTTTG (SEQ ID NO. 21); TNF-alpha downstream primer: ATGGGCTACAGGCTTGTCACTC (SEQ ID NO. 22).
NF-. Kappa.B upstream primer: GCAGCACTACTTCTTGACCACC (SEQ ID NO. 23); NF-. Kappa.B downstream primer: TCTGCTCCTGAGCATTGACGTC (SEQ ID NO. 24).
Adopts beta-actin as an internal reference gene:
beta-actin upstream primer: CACCATTGGCAATGAGCGGTTC (SEQ ID NO. 25); beta-actin downstream primer: AGGTCTTTGCGGATGTCCACGT (SEQ ID NO. 26).
cDNA stock was diluted 4-fold and qPCR reaction system (20. Mu.l) was prepared on ice:
after thoroughly mixing, 20. Mu.L of the reaction solution was sucked into the reaction well, the heat-sealing film was sealed, and the mixture was centrifuged briefly. Detection was performed on a PCR instrument. qPCR reaction procedure was as follows: a pre-denaturation stage, 95 ℃ for 2min;40 cyclic stages (including denaturation, annealing/extension), denaturation 95 ℃,10s, annealing/extension 60 ℃,30s; melting curve phase (instrument default settings); experimental data were obtained for subsequent results analysis.
Experiments were repeated at least three times. The relative expression of each inflammatory factor is calculated by taking reference genes as references. The results (FIG. 3) show that the relative expression levels of inflammatory factors of HaCaT cells pre-protected by transfection of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 are lower than those of LPS stimulated groups to different degrees. The miR-CM2, miR-CM3, miR-CM4 or miR-CM5 pre-protection is indicated to reduce the increase of inflammatory factors caused by LPS stimulation and reduce inflammatory response.
The result shows that the pre-protection of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 can reduce the inflammatory damage of HaCaT cells caused by LPS.
Example 3miR-CM2, miR-CM3, miR-CM4 or miR-CM5 skin care emulsion reduces the thickness of epidermis in skin inflammation of mice caused by ultraviolet irradiation
1) Preparation of miR-CM2, miR-CM3, miR-CM4 or miR-CM5 skin care emulsion
The formula of the miR-CM2 skin care emulsion comprises the following components: calculated according to the weight percentage, EDTA disodium 0.03%, glycerin 4%, xanthan gum 0.1%, p-hydroxyacetophenone 0.2%, montanov L-emulsifier 1%, ARLACEL170 emulsifier 1%, glycerol stearate 0.3%, cetostearyl alcohol 1%, caprylic/capric triglyceride 4%, polydimethylsiloxane 1%, methyl propylene glycol 0.35%, polyethyleneimine-1500% 1%, sodium hyaluronate 1%, miR-CM2 0.75%, and the balance deionized water.
The composition of the miR-CM3 skin care emulsion is the same as that of the miR-CM2 skin care emulsion, and miR-CM2 is replaced by miR-CM 3;
the composition of the miR-CM4 skin care emulsion is the same as that of the miR-CM2 skin care emulsion, and miR-CM2 is replaced by miR-CM 4;
the composition of the miR-CM5 skin care emulsion is the same as that of the miR-CM2 skin care emulsion, and miR-CM2 is replaced by miR-CM5;
according to the above formula, the preparation method comprises the following steps:
firstly, mixing EDTA disodium, glycerol, xanthan gum, p-hydroxyacetophenone, montanov L-emulsifier, ARLACEL170 emulsifier, glycerol stearate, cetostearyl alcohol, caprylic/capric triglyceride, polydimethylsiloxane, methyl propylene glycol and water in advance for emulsification to obtain emulsion;
then, pre-mixing polyethyleneimine-1500 and sodium hyaluronate into a solution, adding miR-CM2 (or miR-CM3 or miR-CM4 or miR-CM5, wherein the miR-CM2, miR-CM3, miR-CM4 and miR-CM5 are nucleic acid molecules obtained by synthesis according to nucleotide sequences shown in sequence tables SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO. 4) into the solution, gently mixing, and standing for 25min to obtain a mixed solution containing miR-CM2 (or miR-CM3 or miR-CM4 or miR-CM 5);
and finally, adding the mixed solution containing miR-CM2 (or miR-CM3 or miR-CM4 or miR-CM 5) into the emulsion obtained by pre-mixing and emulsifying at the temperature below 40 ℃ to obtain the miR-CM2 (or miR-CM3 or miR-CM4 or miR-CM 5) skin care emulsion.
2) Establishment of mouse photoaging model
Kunming mice (females, 6-8 weeks) were randomly divided into seven groups (n=5, 1 control group, 4 experimental group, 1 model group 1, 1 model group 2), and back dehairing treatment. Normal feeding of mice in each group; wherein the control group was not given any treatment; experiment group, model group 1 and model group 2 were subjected to ultraviolet irradiation (UVA irradiation)The frequency is three times per week, and the dosage is 8J/cm 2 For 4 weeks), the four skin care emulsions prepared in the step 1) are respectively applied for treatment after each irradiation of the experimental group; after each irradiation of model group 2, a basic skin care emulsion without miR-CM2/CM3/CM4/CM5 is given (the preparation method is the same as step 1), and only miR-CM2/CM3/CM4/CM5 components are removed for smearing treatment; model group 1 was irradiated with ultraviolet light alone and no treatment was given. All mice were euthanized after 4 weeks. Back skin tissue was collected and fixed in formalin.
3) HE staining
Tissues were dehydrated and embedded in paraffin according to standard procedures. Sections were obtained at 4 μm thickness and stained using Hematoxylin Eosin (HE) staining kit (soribao, beijing).
Hematoxylin-Eosin staining (HE staining) is the most basic staining method in pathological routine tableting. Hematoxylin dye solution is alkaline, and mainly causes chromatin in nuclei and ribosomes in cytoplasm to be purple blue; eosin is an acid dye that primarily reds the cytoplasmic and extracellular matrix components.
Paraffin sections were dewaxed in xylene 2 times for 5-10min each. Gradient ethanol (100%, 95%, 85%, 75%) was rehydrated, 3min per gradient. Distilled water for 2min. Hematoxylin dye liquor is used for dyeing for 2-20min (the specific time is adjusted according to the dyeing result and experimental requirements), and the flooding is removed by washing with distilled water. Differentiation liquid is differentiated for 3min, and is washed for 2 times with tap water for 2min each time. Placing in eosin dye solution for 30s-2min, washing with distilled water for 2-3s, and rapidly dehydrating. Gradient ethanol (75% ethanol, 85% ethanol, 95% ethanol, and 100% ethanol) was used for each rinse for 2-3s. Washing with 100% ethanol for 1min, and observing with a mirror after xylene is transparent for 1min each time.
The skin structure is mainly divided into three layers: epidermis, dermis, and subcutaneous tissue. HE staining can stain various components of tissue cells for comprehensive visualization of tissue architecture. Skin tissue is subjected to HE staining, so that a tissue structure staining picture of the skin can be easily obtained and used for judging various skin indexes, such as epidermis thickness. HE staining results were used to calculate skin thickness by imageJ software, and the statistics are shown on the right side of fig. 4.
The control group corresponds to the Ctrl group in fig. 4.
Experimental groups correspond to those in fig. 4: UV+miR-CM2 group, UV+miR-CM3 group, UV+miR-CM4 group and UV+miR-CM5 group.
Model set 1 corresponds to the UV set in fig. 4.
Model set 2 corresponds to the uv+ base emulsion set in fig. 4.
As a result (shown in fig. 4), it was found that after UV irradiation, the skin thickness of model group 1 (i.e., UV group in fig. 4) was significantly increased compared to the skin thickness of control group (i.e., ctrl group in fig. 4), indicating that the modeling of the mouse photoaging model was successful. And the skin thickness of the model group 1 is not significantly different from that of the model group 2 (namely, the UV+ basic emulsion group in fig. 4), which indicates that the emulsion coated with the miR-CM2/CM3/CM4/CM5 component cannot protect the skin of the mice against the increase of the skin thickness caused by ultraviolet irradiation, while the miR-CM2, miR-CM3, miR-CM4 or miR-CM5 skin-care emulsion protection (namely, the UV+miR-CM2 group, the UV+miR-CM3 group, the UV+miR-CM4 group and the UV+miR-CM5 group in fig. 4) can resist the increase of the skin thickness caused by ultraviolet irradiation, which indicates that the miR-CM2, miR-CM3, miR-CM4 or miR-CM5 skin-care emulsion can significantly inhibit skin inflammation caused by ultraviolet irradiation, reduce the skin thickness of the skin of the treated group and reduce skin irregular proliferation caused by inflammation caused by ultraviolet irradiation.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (8)
1. miRNA from phellinus linteus is characterized by specifically being miR-CM4, and the nucleotide sequence of the miRNA is shown in SEQ ID NO. 3: acguguggauccagacggguu.
2. A miRNA from Phellinus linteus as set forth in claim 1,
the precursor sequence MIR-CM4 of miR-CM4 has a nucleotide sequence shown in SEQ ID NO. 7: cgaguccuuguggauaccaggcugguacaugugaggaugcggauggaaaugcuuugacgaguccguugaacg uguggauccagacggguucuuacgucuugaucgccu;
the DNA of the coding precursor sequence MIR-CM4 has a nucleotide sequence shown in SEQ ID NO. 11.
3. The analogue of miRNA from Phellinus linteus of claim 1,
the miR-CM4 analogues are miR-CM4 mimics:
the sense strand sequence is: 5'-acguguggauccagacggguu-3', as shown in SEQ ID NO. 3;
the antisense strand sequence is: 5'-cccgucuggauccacacguuu-3' as shown in SEQ ID NO. 15.
4. The use of a miRNA from phellinus linteus of claim 1 or an analogue of claim 3, characterized by being the use of miR-CM4 or an analogue thereof for the preparation of a product for preventing or treating skin inflammation.
5. The external preparation for skin containing miR-CM4 according to claim 1, which is characterized in that the content of miR-CM4 in the external preparation for skin is 0.2% -5%.
6. The external skin preparation of claim 5, wherein an emulsion comprising miR-CM4 comprises the following components: 0.01-0.05% of EDTA disodium, 2-5% of glycerol, 0.05-0.2% of xanthan gum, 0.1-0.3% of p-hydroxyacetophenone, 0.5-3% of Montanov L-emulsifier, 0.5-3% of ARLACEL170 emulsifier, 0.1-0.5% of glycerol stearate, 0.5-3% of cetostearyl alcohol, 2-6% of caprylic/capric triglyceride, 0.5-3% of polydimethylsiloxane, 0.1-0.5% of methyl propylene glycol, 0.5-3% of polyethyleneimine-1500, 0.5-3% of sodium hyaluronate, 0.2-5% of miR-CM and the balance deionized water.
7. The external preparation for skin according to claim 6, comprising the following components: EDTA disodium 0.03%, glycerol 4%, xanthan gum 0.1%, p-hydroxyacetophenone 0.2%, montanov L-emulsifier 1%, ARLACEL170 emulsifier 1%, glyceryl stearate 0.3%, cetostearyl alcohol 1%, caprylic/capric triglyceride 4%, polydimethylsiloxane 1%, methyl propylene glycol 0.35%, polyethyleneimine-1500 1%, sodium hyaluronate 1%, miR-CM 4.75%, and deionized water in balance.
8. Use of the external preparation for skin according to any one of claims 5 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311499739.7A CN117625606A (en) | 2021-12-21 | 2021-12-21 | miR-CM4 of Phellinus linteus and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311499739.7A CN117625606A (en) | 2021-12-21 | 2021-12-21 | miR-CM4 of Phellinus linteus and application thereof |
| CN202111573093.3A CN114525278B (en) | 2021-12-21 | 2021-12-21 | miRNA of Phellinus linteus and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111573093.3A Division CN114525278B (en) | 2021-12-21 | 2021-12-21 | miRNA of Phellinus linteus and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117625606A true CN117625606A (en) | 2024-03-01 |
Family
ID=81618866
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111573093.3A Active CN114525278B (en) | 2021-12-21 | 2021-12-21 | miRNA of Phellinus linteus and application thereof |
| CN202311503085.0A Pending CN118109461A (en) | 2021-12-21 | 2021-12-21 | MiR-CM5 of Phellinus linteus and application thereof |
| CN202311499739.7A Pending CN117625606A (en) | 2021-12-21 | 2021-12-21 | miR-CM4 of Phellinus linteus and application thereof |
| CN202311502403.1A Pending CN117625607A (en) | 2021-12-21 | 2021-12-21 | miR-CM3 of Phellinus linteus and application thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111573093.3A Active CN114525278B (en) | 2021-12-21 | 2021-12-21 | miRNA of Phellinus linteus and application thereof |
| CN202311503085.0A Pending CN118109461A (en) | 2021-12-21 | 2021-12-21 | MiR-CM5 of Phellinus linteus and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311502403.1A Pending CN117625607A (en) | 2021-12-21 | 2021-12-21 | miR-CM3 of Phellinus linteus and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN114525278B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804960B1 (en) * | 2000-02-11 | 2005-06-24 | Lvmh Rech | NOVEL OLIGONUCLEOTIDES AND USE OF OLIGONUCLEOTIDES MODULATING THE EXPRESSION OF TYROSINASE AND TYROSINASE-RELATED-PROTEIN 1 AS DEPIGMENTING AGENTS |
| CN110638829A (en) * | 2019-03-01 | 2020-01-03 | 上海澄穆生物科技有限公司 | Preparation method and application of plateau catechin-loaded lentinan complex |
| CN112263502A (en) * | 2020-07-31 | 2021-01-26 | 上海澄穆生物科技有限公司 | Application of phenethyl and styryl resorcinol glycoside compounds in anti-inflammatory and anti-aging skin care products |
-
2021
- 2021-12-21 CN CN202111573093.3A patent/CN114525278B/en active Active
- 2021-12-21 CN CN202311503085.0A patent/CN118109461A/en active Pending
- 2021-12-21 CN CN202311499739.7A patent/CN117625606A/en active Pending
- 2021-12-21 CN CN202311502403.1A patent/CN117625607A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114525278A (en) | 2022-05-24 |
| CN118109461A (en) | 2024-05-31 |
| CN117625607A (en) | 2024-03-01 |
| CN114525278B (en) | 2023-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2217704B1 (en) | Method for the promotion of angiogenesis, vascularization, or vascular repair or for the inhibition of tumor angiogenesis | |
| US9303261B2 (en) | Composition for controlling chromogenesis including microRNA | |
| Chen et al. | MicroRNA and heme oxygenase-1 in allergic disease | |
| Li et al. | Polysaccharide of atractylodes macrocephala koidz activated T lymphocytes to alleviate cyclophosphamide-induced immunosuppression of geese through novel_mir2/CD28/AP-1 signal pathway | |
| WO2009039743A1 (en) | Sirnas useful for inhibiting expression of tyrosinase gene, the compositions comprising the sirnas and their uses | |
| CN114525278B (en) | miRNA of Phellinus linteus and application thereof | |
| US20140336371A1 (en) | Sirna molecule for inhibiting growth of melanin and application thereof | |
| EP3766503B1 (en) | Microrna-210 inhibitor for use in treating inflammatory skin diseases | |
| US10519440B2 (en) | Composition and method of using miR-302 precursors as drugs for treating Alzheimer's diseases | |
| CN110205366B (en) | Method for screening endogenous aging target of skin, active substance for improving endogenous aging of skin and screening method thereof | |
| TWI762460B (en) | A COMPOSITION AND METHOD OF USING miR-302 PRECURSORS AS DRUGS FOR TREATING ALZHEIMER'S DISEASES | |
| CN114149992B (en) | MiR-CM1 of Phellinus linteus and application thereof | |
| CN110205367B (en) | Method for screening active substance for protecting skin cell telomere | |
| JP2021528984A (en) | In vitro induction of adult stem cell expansion and induction | |
| CN113730430A (en) | Application of small molecular saussurea involucrate polysaccharide in adiponectin secretion regulation and preparation method thereof | |
| CN113876645B (en) | Usnea barbata extract, application thereof and skin external preparation containing same | |
| CN115381849B (en) | Active ingredient of anti-oral tumor medicine and application thereof | |
| WO2020151726A1 (en) | Oligonucleotides for skin care | |
| CN115068387B (en) | Plant composition and application thereof in cosmetics | |
| CN118403094A (en) | Keratinocyte function protective agent and preparation method and application thereof | |
| CN117736219A (en) | Sesquiterpenoids derived from white ginseng fungus, preparation method thereof and application thereof in preparing anti-inflammatory drugs | |
| CN118846075A (en) | Application of miR-125a-5p/let-7e-5p antagonist in treatment of non-alcoholic fatty liver disease | |
| CN116870174A (en) | DNA tetrahedral complex and application thereof in preparation of medicine for treating psoriasis | |
| CN117625600A (en) | Recombinant miRNA combination with sensitive muscle repair effect and application | |
| CN111560376A (en) | siRNA for specifically inhibiting OLFM4 gene expression and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |